From Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug:

Valerie Odegard
Valerie Odegard

Portrait of Silverback Therapeutics Chief Scientific Officer Valerie Odegard, courtesy of the company.